This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
PerkinElmer's (PKI) Arm Introduces Two CE-Marked Assays
by Zacks Equity Research
PerkinElmer's (PKI) company launches two CE-marked antibody tests that can support the analysis of the immune response to COVID-19.
Bruker (BRKR) Debuts Module on Ultima Multiphoton Microscopes
by Zacks Equity Research
Bruker's (BRKR) NeuraLight 3D Ultra module offers revolutionary 3D holographic photostimulation to support neuroscience and optogenetics research applications.
Here's Why You Should Hold on to Surmodics (SRDX) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Surmodics (SRDX) owing to its consistent efforts to boost R&D.
West Pharmaceutical's (WST) Syringe System to Improve Outcome
by Zacks Equity Research
West Pharmaceutical's (WST) new CZ syringe system size is expected to enable a simpler patient experience and aid pharmaceutical companies in providing better access to their products.
Here's Why You Should Retain West Pharmaceutical (WST) Now
by Zacks Equity Research
West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.
How Much Upside is Left in AMN Healthcare (AMN)? Wall Street Analysts Think 32%
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 32% in AMN Healthcare (AMN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
What's in Store for Patterson Companies' (PDCO) Q4 Earnings?
by Zacks Equity Research
Patterson Companies' (PDCO) fiscal fourth-quarter results are likely to reflect improvement at the Animal Health segment.
Boston Scientific (BSX) to Broaden Stent Portfolio With Buyout
by Zacks Equity Research
According to Boston Scientific (BSX), M.I.Tech's product offerings complement the company's existing stent portfolio, including the differentiated AXIOS Stent and Electrocautery Enhanced Delivery System.
3 Reasons Why Growth Investors Shouldn't Overlook AMN Healthcare (AMN)
by Zacks Equity Research
AMN Healthcare (AMN) could produce exceptional returns because of its solid growth attributes.
ResMed (RMD) Inks Deal to Acquire MEDIFOX DAN in Germany
by Zacks Equity Research
ResMed's (RMD) acquisition of a renowned out-of-hospital software solutions company is expected to strengthen its SaaS business.
BD's (BDX) Latest Collaboration to Enhance Patient Care
by Zacks Equity Research
BD's (BDX) new partnership is expected to increase efficiency for new clinical trials, generate evidence, support new claims for its products and streamline medical device regulatory submissions.
Here's Why You Should Hold Quest Diagnostics (DGX) Stock Now
by Zacks Equity Research
Investors are optimistic about Quest Diagnostics (DGX) owing to a strong recovery in its base business and encouraging 2022 guidance.
Here's Why You Should Hold on to Ecolab (ECL) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Ecolab (ECL) owing to its solid product portfolio.
Here's Why You Should Hold on to Stryker (SYK) Stock for Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure weighs on it.
Charles River (CRL) to Create New Gene Therapy for Hemophilia A
by Zacks Equity Research
Charles River (CRL) will work with ASC Therapeutics to manufacture a second-generation gene therapy for hemophilia A.
Here's Why You Should Hold on to Teleflex (TFX) Stock for Now
by Zacks Equity Research
Investors are optimistic about Teleflex's (TFX) better-than-expected results and strong growth within the vascular business.
Align (ALGN) Hurt by Dental Practice Closures, FX Headwind
by Zacks Equity Research
Align (ALGN) competes with products similar to Invisalign Technology, such as the products from Ormco Orthodontics, a division of Sybron Dental Specialties.
Here's Why You Should Retain Fresenius Medical (FMS) Stock Now
by Zacks Equity Research
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
CONMED (CNMD) to Expand Orthopedic Portfolio With Buyout
by Zacks Equity Research
CONMED's (CNMD) completion of In2Bones Global buyout will expand its orthopedic portfolio.
Humana (HUM) to Offer Home Care Model to Virginia's MA Members
by Zacks Equity Research
Humana (HUM) expands the customer reach of its unit's value-based home care model to Virginia, with an aim to offer better in-home care services to the state's Medicare Advantage members.
Here's Why Investors Should Retain Chemed (CHE) Stock Now
by Zacks Equity Research
Strong performance across Chemed's (CHE) Roto-Rooter arm and increased home-based admissions raise investors' confidence.
Here's Why Investors Should Retain SmileDirectClub (SDC) Now
by Zacks Equity Research
Investors are optimistic about SmileDirectClub's (SDC) better-than-expected revenues and new product launches.
Here's Why You Should Hold on to Accuray (ARAY) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Accuray (ARAY) owing to its solid global reach.
Here's Why You Should Retain Intuitive Surgical (ISRG) Stock
by Zacks Equity Research
Intuitive Surgical (ISRG) continues to gain traction from the improving adoption of the da Vinci Surgical System. Higher production costs are a woe.
AMN Healthcare Services (AMN) Stock Moves -0.41%: What You Should Know
by Zacks Equity Research
AMN Healthcare Services (AMN) closed at $100.27 in the latest trading session, marking a -0.41% move from the prior day.